Biomarkers in Atopic Dermatitis and Psoriasis

BIOMAP examines the causes and mechanisms of atopic dermatitis and psoriasis by identifying the biomarkers responsible for the variation in disease outcome.

Taking advantage of recent technical developments in translational medicine, the project will enable drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics.

vision auge

Our Vision

BIOMAP aims to better define the heterogeneity and homogeneous aspects of atopic dermatitis and psoriasis and to develop new concepts for taxonomy and patient stratification.

BIOMAP Members

BIOMAP is a public-private partnership uniting 34 academic and industry partners from 13 countries to address key unmet needs in treating atopic dermatitis and psoriasis. Patient & Advisory Boards complement the expertise.

BIOMAP Timeline

01/04/2019

Project start

09/04/2019

Kick-off meeting, launch of website and Twitter account

Follow us on Twitter and LinkedIn

09/04/2019

BIOMAP Data and Analysis Portal launched

31/12/2019

Two publications published in 2019

01/06/2020

Novartis joins BIOMAP

03/12/2020

University of Edinburgh joins BIOMAP

31/12/2020

Five publications published in 2020

01/02/2021

Almirall joins BIOMAP

07/04/2021

BIOMAP Clip released

Watch our clip at the top of the page

10/06/2021

First lay summary published

16/06/2021

BIOMAP Glossary published

19/11/2021

IHI Mid-Term Review

31/12/2021

Seven publications published in 2021

28/03/2022

Twitter

200 Twitter followers reached

01/05/2022

Medical Center – University of Freiburg joins BIOMAP

30/06/2022

Executive Management Team meets in Copenhagen

11/07/2022

Two new lay summaries published, in total four available

04/10/2022

Annual Consortium Meeting in Kiel

29/10/2022

World Psoriasis Day 2022 and Website Relaunch

31/12/2022

Ten publications published in 2022

01/02/2023

Executive Management Team and Task Force Leaders meet in Frankfurt

16/03/2023

IHI article on BIOMAP publication published: Examining data in new ways highlights genetic differences in psoriatic skin

02/04/2023

Executive Management Team and Task Force Leaders meet in Frankfurt

05/06/2023

Four new lay summaries published, in total eight available

21/09/2023

Annual Consortium Meeting in Brussels

27/11/2023

Executive Management Team and Task Force Leaders meet in London

31/03/2025

End of project

Voices of BIOMAP

“By joining the expertise from academia and pharmaceutical industry, and by analysing a collection of harmonised clinical and molecular data from nearly a million sufferers, unprecedented in scale and depth, ranging from multi-dimensional datasets on single cells (skin and blood) through to whole populations, atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”

Prof. Stephan Weidinger
Christian-Albrechts-Universität zu Kiel
Coordinator

“BIOMAP presents a major opportunity to improve the lives of people with skin disease – we need information on why and who is going to develop severe disease, and also new approaches to treatment. Involving a Patient Advisory Group puts the needs of the patients at the heart of the project from the very beginning. By providing a European-wide platform for collaboration, BIOMAP will enable sharing of know-how and data about atopic dermatitis and psoriasis so that we can all work together like never before.”

Helen McAteer
Chief Executive of the Psoriasis Association
BIOMAP Patient Advisory Group

“BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases.”

Dr Witte Koopmann
Co-project lead
LEO Pharma

“The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene.”

Professor Catherine Smith
Co-coordinator
King’s College London